Valuation: XORTX Therapeutics Inc.

Market Cap 3.49M 2.49M 2.17M 2.05M 1.86M 239M 3.5M 24.56M 9.48M 121M 9.35M 9.15M 391M P/E 2024
-0.98x
P/E 2025 -1x
Enterprise Value 2.66M 1.9M 1.66M 1.56M 1.42M 182M 2.67M 18.73M 7.23M 92.66M 7.13M 6.98M 298M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
92.16%
Yield 2024 *
-
Yield 2025 -
1 day+4.59%
1 month+14.75%
3 months+5.28%
6 months-0.31%
Current year-17.14%
1 month 2.79
Extreme 2.79
3.33
Current year 2.42
Extreme 2.425
4.83
1 year 2.42
Extreme 2.425
9.85
3 years 2.42
Extreme 2.425
49.5
5 years 2.42
Extreme 2.425
355.5
10 years 2.42
Extreme 2.425
449.05
Manager TitleAgeSince
Chief Executive Officer 28 15/06/2026
Chief Executive Officer 66 09/01/2018
Director of Finance/CFO 62 19/12/2024
Director TitleAgeSince
Director/Board Member 66 09/01/2018
Director/Board Member 50 24/03/2026
Director/Board Member - 24/03/2026
Date Insider Type Main position Quantity % Market Cap. Importance
02/02/26 Other

Director

0 0%
02/02/26 Option

Director

20,000 0.2873%
07/01/26 Other

Director

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
+4.59%0.00% - - 3.43M
-0.31%+5.79%+48.93%+97.53% 70.88B
+0.39%+2.06%+40.91%+78.49% 62.49B
-3.21%-7.27%-17.73%+351.98% 26.21B
+0.50%+7.13%+29.43%+15.48% 26.34B
-2.64%-0.69%-0.26%-11.90% 24.13B
+0.71%+8.03%+27.22%-13.18% 20.72B
-1.26%-7.81%+169.33%+302.38% 15.36B
-0.22%+3.99%+44.28%+173.35% 14.46B
+0.73%+1.71%-7.18%+886.19% 14.25B
Average -0.07%+1.65%+37.22%+208.92% 30.54B
Weighted average by Cap. -0.47%+1.44%+36.51%+147.97%

Financials

2024 2025
Net sales - -
Net income -3.31M -2.37M -2.06M -1.95M -1.77M -227M -3.33M -23.33M -9M -115M -8.89M -8.69M -371M -2.66M -1.9M -1.65M -1.56M -1.42M -182M -2.67M -18.7M -7.22M -92.51M -7.12M -6.96M -298M
Net Debt -2.43M -1.74M -1.52M -1.43M -1.3M -167M -2.45M -17.14M -6.62M -84.79M -6.53M -6.38M -273M -827K -591K -515K -486K -442K -56.66M -831K -5.82M -2.25M -28.81M -2.22M -2.17M -92.69M
Logo XORTX Therapeutics Inc.
XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.
Employees
-

Annual profits - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!